Seno Medical Instruments CEO Janet Campbell to Step Down and Assume New Board Level Role

SAN ANTONIO, Sept. 9, 2015 /PRNewswire/ -- Seno Medical Instruments, Inc., a medical device company that is an industry leader in developing opto-acoustics for breast diagnostic imaging, today announced that its founder and CEO, Janet Campbell, has decided to step down from her current role.  Campbell launched Seno ten years ago in San Antonio after a successful career in the medical device industry and venture capital arena.  During her time at Seno, Ms. Campbell developed the first commercial opto-acoustic clinical device in the world, and built a world class team that brought opto-acoustics to its first clinical application.  Under her leadership, Seno launched and completed a multi-center trial (16 U.S. sites) enrolling 2100 subjects.  Participating clinical trial sites are among the leading breast centers in the country.  Seno's technology has obtained regulatory approval outside the US.  In the course of developing Seno's groundbreaking technology Ms. Campbell raised over $100M dollars. Campbell noted "it was a hard decision, but after ten years at the helm, I believe it is time to transition the leadership of Seno to a CEO who can take what we have built and optimize its commercialization.  My passion is finding a new technology, identifying, developing and building a team and pursuing a successful outcome."

Dr. Harry Jacobson, of MedCare Investment Funds and the Chairman of Seno's Board of Directors said of Campbell: "Janet has been one of the best CEO's I have had the pleasure of working with and she has done a remarkable job of building Seno and making it a recognized leader in our industry." Jacobson went on to note: "While we begin the process of finding a new CEO, Janet will remain as a special advisor to the Board to assist us in a smooth transition."

Ms. Campbell will be pursuing her new venture, Dominion Medical.

About Seno Medical Instruments, Inc.

Seno Medical Instruments, Inc. is a San Antonio, Texas-based medical imaging company committed to the development and commercialization of a new modality in cancer diagnosis: opto-acoustic imaging. Seno's Imagio breast imaging system fuses opto-acoustic technology with ultrasound to generate functional and anatomical images of the breast. The opto-acoustic images provide a unique blood map around suspicious breast masses while the ultrasound provides a traditional anatomic image. Through the appearance or absence of the two hallmark indicators of cancer – angiogenesis and deoxygenation – Seno believes that Imagio images will be a more effective tool to help radiologists confirm or rule out malignancy than current diagnostic imaging modalities – without exposing patients to potentially harmful ionizing radiation (x-rays) or contrast agents. Seno's platform technology may also address other disease applications in organs other than the breast, as well as assessing other breast problems, such as early response to chemotherapy or hormonal treatments of breast cancer. To learn more about Seno's opto-acoustic imaging technology and applications, visit www.SenoMedical.com

Media Contact

Brian Baxter 
Lazar Partners Ltd. 
Tel: +1 212-867-1762
Email: [email protected]

SOURCE Seno Medical Instruments, Inc.

Related Links

http://www.senomedical.com/